Imminent Patent Expiry of Key Blockbuster Drugs to Benefit Generics Manufacturers, Anticipates Frost & Sullivan

Imminent Patent Expiry of Key Blockbuster Drugs to Benefit Generics Manufacturers, Anticipates Frost & Sullivan PR Newswire LONDON, June 1, 2012 - Patent Expiry of Several Key Blockbuster Drugs worth $150 billion between 2010 and 2017 Sets Stage for Entry of Generics Manufacturers LONDON, June 1, 2012 /PRNewswire/ -- The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiration of key blockbuster drugs and the judicious cost containment efforts of governments and healthcare service providers worldwide. At the same time, the balance in terms of healthcare expenditure and sales revenue is poised to shift from developed to emerging markets such as India, China, Brazil, Russia, Turkey and South Korea, as huge potential still remains untapped in these countries. New analysis from Frost & Sullivan (http://www.pharma.frost.com), Generic Pharmaceuticals Market – A Global Analysis, finds that the market earned revenues of $123.85 billion in 2010 and estimates this to reach $231.00 billion in 2017 at a compound annual growth rate (CAGR) of 9.29 per cent from 2011- 2018. Regions covered in the research include the United States, Europe (Germany, the United Kingdom, France, Spain, and Italy) and Asia (India and China).